Cystic kidney disease, unspecified
ICD-10 Q61.9 is a billable code used to indicate a diagnosis of cystic kidney disease, unspecified.
Cystic kidney disease encompasses a range of congenital malformations characterized by the presence of cysts in the kidneys. These cysts can vary in size and number, leading to renal dysfunction. The condition may arise from genetic mutations or developmental anomalies during fetal growth. In pediatric patients, cystic kidney disease can manifest as renal agenesis, where one or both kidneys fail to develop, or as polycystic kidney disease, which is characterized by the formation of numerous cysts that can impair kidney function. Other related congenital anomalies include bladder exstrophy, where the bladder is exposed outside the body, and posterior urethral valves, which can obstruct urinary flow and lead to hydronephrosis. Accurate diagnosis and coding are essential for appropriate management and treatment, as these conditions can lead to significant morbidity if not addressed early.
Pediatric documentation should include growth parameters, developmental milestones, and specific symptoms related to renal function.
Common scenarios include newborns presenting with abdominal masses, hypertension, or urinary tract infections due to congenital anomalies.
Considerations include the need for multidisciplinary care involving nephrology, urology, and genetics.
Genetic documentation should include family history, results of genetic testing, and any syndromic associations.
Genetic counseling scenarios may involve families with a history of cystic kidney disease or related syndromes.
Considerations include the implications of genetic findings for family planning and the potential for other affected family members.
Used to evaluate renal structure in suspected cystic kidney disease.
Document indications for ultrasound and findings.
Pediatric specialists should ensure age-appropriate imaging protocols.
Accurate coding of cystic kidney disease is crucial for appropriate management, treatment planning, and ensuring that patients receive the necessary follow-up care. It also impacts reimbursement and data collection for congenital conditions.
